NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$37.09 +0.13 (+0.35 %)
(As of 07/22/2018 08:29 AM ET)
Previous Close$37.09
Today's Range$36.1868 - $37.21
52-Week Range$15.15 - $45.61
Volume161,205 shs
Average Volume207,501 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Deciphera Pharmaceuticals logoDeciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Debt-to-Equity Ratio0.01
Current Ratio11.12
Quick Ratio11.12

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.64 per share
Price / Book6.58

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees65
Outstanding Shares37,540,000
Market Cap$1,392.32

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) released its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.04. View Deciphera Pharmaceuticals' Earnings History.

What price target have analysts set for DCPH?

7 Wall Street analysts have issued 1-year price objectives for Deciphera Pharmaceuticals' shares. Their predictions range from $33.00 to $65.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $50.8333 in the next year. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Ratings for Deciphera Pharmaceuticals.

What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Deciphera Pharmaceuticals' key competitors?

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the folowing people:
  • Dr. Michael D. Taylor, Pres, CEO & Director (Age 63)
  • Dr. Daniel L. Flynn, Founder & Chief Scientific Officer (Age 63)
  • Mr. Christopher J. Morl, Chief Bus. Officer (Age 59)
  • Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 47)
  • Mr. Thomas W. Fredrick, Head of Legal Affairs

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Has Deciphera Pharmaceuticals been receiving favorable news coverage?

News stories about DCPH stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Deciphera Pharmaceuticals earned a news impact score of 0.15 on Accern's scale. They also gave headlines about the company an impact score of 45.89 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $37.09.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $1.39 billion. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]


MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.